Teams responsible for setting strategy and evaluating assets in a therapeutic area face many challenges, including assessing the merit of programs targeted to specific diseases and helping management decide what to fund. We have years of experience working with client teams to elicit insights that inform their strategy.

Equinox Group’s Disease Target Assessment tools help:

• Identify the clinical attributes that represent the best targets for differentiation in selected diseases
• Tie specific clinical claims for internal and external R&D programs to commercial value
• Gain an early read on reimbursement potential and how payers are likely to value trade-offs among product attributes
• Bridge the divides that can arise among discovery, development, and commercial teams, helping create consensus to set goals and monitor progress over time
• Provide a valid basis for comparing the innovation and value of programs across diseases and therapeutic areas